Monsenso expands in the Middle East with new million deal with global pharmaceutical company

Monsenso expands in the Middle East with new million deal with global pharmaceutical company

Monsenso has entered a new million agreement with a global pharmaceutical company and hereby expands its activities to six countries in the Middle East. As part of the agreement, Monsenso will provide its solution for patient monitoring and treatment support in the United Arab Emirates, Saudi Arabia, Oman, Kuwait, Qatar and Bahrain.

Monsenso’s solution will be used to support the treatment of depression and schizophrenia. Patients are provided with an app, which is used to collect real-time patient-reported information and to give patients access to information about their disorder between consultations. Therapists gain access to a clinical web portal and can follow their patients remotely and gain valuable information about behavior, medication intake and symptoms and thus be able to provide a data-driven treatment and allow for proactive follow-up.
In addition, the solution supports communication between patients and therapists.

“We are very pleased with this agreement, which contributes to both expanding our geographic market coverage and our business with pharmaceutical companies in line with our growth strategy. ” says Thomas Lethenborg, CEO of Monsenso. “Depression and schizophrenia are among the most costly disorders for society and have major consequences for affected patients and relatives. Therefore, we are proud to be able to contribute to better treatment within these disease areas.”

The project will not affect Monsenso’s previously communicated plans and guidance for the 2020 financial year.

To read the Danish version, click here.

For additional information contact:
Bettina van Wylich-Muxoll
Chief Marketing Officer

Why pharma can benefit from mHealth solutions

Why pharma can benefit from mHealth solutions

Pharma can benefit from mHealth solutions by using them in clinical trials, and by offering them to healthcare providers as part of a comprehensive treatment solution.

Meeting the needs of healthcare providers

The healthcare industry is widely adopting digital technologies. But, today’s healthcare providers are extremely busy between seeing patients and filing paperwork, which limits their time online.

Nowadays, more than 80% of HCPs have a desktop/laptop computer and a smartphone, and 72% own a tablet. [1] Mobile assets are rapidly becoming components in the clinical environment.

Pharma can benefit from mHealth solutions since many healthcare providers would like to find new evidence-based medicine to provide better treatment for their patients, but in many cases, they don’t have time.  In fact, according to a survey conducted by Publicis on Sermo, 81% of clinicians want higher quality pharma representatives capable of having serious discussions of multiple therapeutic options. [2]

Pharma can benefit from mHealth solutions by offering  them to healthcare providers, and  help them satisfy their needs – improving health outcomes, information sharing, and staying updated with the latest treatments.  Providing this type of solution will not only facilitate their customers’ jobs, but they will also open new doors and new opportunities to propose comprehensive treatment solutions.

Pharma should reach out to healthcare providers and offer them digital tools, content, and communities that can help them do their jobs more efficiently.

Improving outcomes in clinical trials

Given the challenges faced during clinical trials, it is only natural that pharma turns to mHealth solutions to help them recruit patients, as well as monitoring and measuring their results.

Subjects are much more likely to participate in a study if they have the possibility to raise their concerns or ask any questions 24/7.

Pharma can benefit from mHealth solutions, since these tools can collect even more data in real-time, improve efficiencies in time and costs, shorten timelines, as well as increase patient satisfaction, retention, and future recruitment.

A key element of success when using mHealth solutions for clinical trials is the ease with which mHealth solutions can collect data, and how that information is integrated into the whole clinical database. These data integrations should be done as closely as possible to real-time, making it easy for clinicians to visualise all the patients’ data.

Conducting clinical studies using mobile devices can help collect and monitor behavioural data and vital signs in patients. These solutions can also work as medication reminders and gather patient feedback – all these improve the decision-making process when developing new medicines.

Monsenso can provide Pharma companies with  a customised, white-label mHealth solution for their clients and to use on clinical trials. If you are interested in learning more about this, click here.


[1]. Publicis Healthcare Communications Group. Publicis Touchpoint Solutions, Inc. (2012). What Physicians Want!
[2] Manhattan Research. Unknown Author. (2013). Taking the pulse 2013.
[3] MHealth in Clinical Research. Denise, Myshko. Pharma Voice. (2016, October)